Drugs / SYHA1801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04309968 | Apr 2020 → Dec 2022 | cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-08-21 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NEW TARGET ANTI-TUMOR DRUG "SYHA1801" WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-08-21 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NEW TARGET ANTI-TUMOR DRUG "SYHA1801" WAS GRANTED CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYHA1801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04309968 ↗ |
| Action | Inhibit | “a BRD4 inhibitor” NCT04309968 ↗ |
| Route | Oral | “administered orally” NCT04309968 ↗ |
| Target | BRD4 | “a BRD4 inhibitor” NCT04309968 ↗ |